Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials

摘要: Background: Many placebo-controlled trials have demonstrated the efficacy of individual pharmacotherapies approved for smoking cessation. However, few direct or indirect comparisons such interventions been conducted. We performed a meta-analysis to compare treatment effects 7 pharmacologic Methods: searched US Centers Disease Control and Prevention9s Tobacco Information Prevention database as well MEDLINE, EMBASE Cochrane Library published reports placebo-controlled, double-blind randomized controlled included studies that reported biochemically validated measures abstinence at 6 12 months. used hierarchical Bayesian random-effects model summarize results each intervention. Results: identified 70 69 involving total 32 908 patients. Six studied were found be more efficacious than placebo: varenicline (odds ratio [OR] 2.41, 95% credible interval [CrI] 1.91–3.12), nicotine nasal spray (OR 2.37, CrI 1.12–5.13), bupropion 2.07, 1.73–2.55), transdermal 1.69–2.62), tablet 2.06, 1.12–5.13) gum 1.71, 1.35–2.21). Similar obtained regardless which measure was used. Although point estimate favoured inhaler over placebo 2.17), these not conclusive because unity (95% 0.95–5.43). When all in same model, placebo. In our analysis data from control arms, we superior 2.18, 1.09–4.08). Interpretation: Varenicline, 5 replacement therapies promoting